Valuation: Repligen Corporation

Market Cap 10B 8.88B 8.31B 7.57B 14.25B 963B 14.45B 101B 38.91B 490B 37.55B 36.74B 1,575B P/E 2026 *
234x
P/E 2027 * 103x
Enterprise Value 9.74B 8.65B 8.09B 7.37B 13.88B 938B 14.07B 97.84B 37.88B 477B 36.56B 35.77B 1,534B EV / Sales 2026 *
11.8x
EV / Sales 2027 * 9.8x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 week-5.54%
Current month-6.73%
1 month+8.37%
3 months+30.11%
6 months+54.94%
Current year+13.25%
1 week 158.35
Extreme 158.35
173.65
1 month 139.45
Extreme 139.45
173.65
3 years 86.86
Extreme 86.86
194.4
5 years 86.86
Extreme 86.86
264
10 years 24.04
Extreme 24.04
281
Manager TitleAgeSince
Chief Executive Officer 56 2024-08-31
Director of Finance/CFO 52 2023-09-24
Chief Tech/Sci/R&D Officer - 2025-07-31
Director TitleAgeSince
Director/Board Member 60 2014-06-11
Director/Board Member 67 2015-09-30
Director/Board Member 61 2020-02-29
Change 5-day change 1-year change 3-year change Capi.($)
-6.73%+5.08%+27.75%+4.48% 10.85B
-2.17%-4.33%-27.56%-0.17% 171B
+0.17%-2.34%-8.83%+10.31% 110B
-0.88%+1.19%-25.04%-0.11% 106B
-0.69%-0.07%-47.78%-12.45% 75.99B
+3.17%-0.03%-0.64%+72.13% 57.3B
-0.52%-0.65%-6.74%-31.12% 48.76B
-1.89%+2.09%+12.61%+58.15% 50.19B
-0.85%+0.85%-16.51%+18.41% 41.14B
-0.07%-1.42%+30.49%-7.58% 32.56B
Average -0.39%-0.28%-6.22%+11.20% 77B
Weighted average by Cap. -0.67%-1.02%-15.74%+8.87%

Financials

2026 *2027 *
Net sales 827M 735M 687M 626M 1.18B 79.63B 1.19B 8.31B 3.22B 40.55B 3.11B 3.04B 130B 976M 867M 811M 739M 1.39B 93.98B 1.41B 9.81B 3.8B 47.86B 3.66B 3.59B 154B
Net income 41.92M 37.24M 34.82M 31.73M 59.74M 4.04B 60.56M 421M 163M 2.06B 157M 154M 6.6B 98.84M 87.79M 82.1M 74.81M 141M 9.52B 143M 993M 384M 4.85B 371M 363M 15.57B
Net Debt -265M -235M -220M -200M -377M -25.5B -383M -2.66B -1.03B -12.99B -994M -973M -41.72B -438M -389M -364M -332M -624M -42.17B -633M -4.4B -1.7B -21.48B -1.64B -1.61B -68.99B
Logo Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its franchises include filtration, chromatography, process analytics and proteins. Its filtration franchise includes product offering covering upstream and downstream technologies. Its filtration products include XCell Alternating Tangential Flow (ATF) Cell Retention Systems, Flat Sheet Cassettes, Hollow Fiber Consumables, Tangential Flow Filtration Systems and Fluid Management. Its chromatography franchise includes products used in downstream purification, development, manufacturing and quality control of biological drugs. Its chromatography franchise includes OPUS Pre-Packed Columns, KRM Chromatography Systems and other additional chromatography products. Its process analytics include Downstream process analytical technology (PAT) and Upstream PAT. Its Proteins include Protein A Affinity Ligands, AVIPure Resins for New Modalities and Growth Factors.
Employees
-
Date Price Change
26-10-01 €158.60 -6.73%
26-09-30 €170.05 -0.90%
26-09-29 €171.60 +0.26%
26-09-28 €171.15 +2.76%
26-09-25 €166.55 -0.80%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
177.23USD
Average target price
189.70USD
Spread / Average Target
+7.04%

Quarterly revenue - Rate of surprise